OnKure Therapeutics (OKUR) to Release Earnings on Monday

OnKure Therapeutics (NASDAQ:OKUR) is projected to announce its results before the market opens on Monday, March 9th. Analysts expect the company to announce earnings of ($1.15) per share for the quarter.

OnKure Therapeutics Stock Up 1.9%

NASDAQ:OKUR opened at $2.71 on Monday. The business’s 50-day simple moving average is $2.75 and its two-hundred day simple moving average is $2.83. OnKure Therapeutics has a 52 week low of $1.70 and a 52 week high of $5.60. The stock has a market cap of $36.72 million, a PE ratio of -0.57 and a beta of 0.45.

Hedge Funds Weigh In On OnKure Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in OKUR. XTX Topco Ltd purchased a new position in OnKure Therapeutics during the 2nd quarter valued at approximately $25,000. Rangeley Capital LLC bought a new position in shares of OnKure Therapeutics during the 2nd quarter valued at approximately $71,000. Shay Capital LLC grew its holdings in shares of OnKure Therapeutics by 417.8% in the second quarter. Shay Capital LLC now owns 782,046 shares of the company’s stock valued at $1,869,000 after purchasing an additional 631,008 shares in the last quarter. Rosalind Advisors Inc. bought a new stake in OnKure Therapeutics in the fourth quarter worth $2,118,000. Finally, Renaissance Technologies LLC increased its position in OnKure Therapeutics by 40.7% in the fourth quarter. Renaissance Technologies LLC now owns 247,350 shares of the company’s stock worth $717,000 after purchasing an additional 71,600 shares during the last quarter. 90.98% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of OnKure Therapeutics in a research note on Monday, December 22nd. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $32.00.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.